
**A reverse vaccinology approach to identifying subunit
proteins for use in vaccines against *Brachyspira pilosicoli*
infections in humans and animals**

Abdolreza Movahedi

DVM

Tehran University

IRAN

Division of Health Sciences

Murdoch University

Western Australia

This thesis is presented for the degree of Doctor of Philosophy of

Murdoch University

2008

Dedicated

To

My loving parents who first sparked my interest in science

To

**My beloved wife, Zahra, and our children, Amin and Mahdi,
who has been a great source of inspiration and encouragement**

A. Movahedi

THESIS DECLARATION

I declare that this thesis is my own account of my research and contains as its main content work which has not previously been submitted for a degree at any tertiary education institution.

.....
Abdolreza Movahedi

ABSTRACT

The anaerobic intestinal spirochaete *Brachyspira pilosicoli* is the causative agent of “intestinal spirochaetosis” (IS), a disease of humans and a number of animal species. IS has been reported in adults and children worldwide but the prevalence in people living in poor hygienic conditions, indigenous populations, homosexual males, and in immunocompromised people is much higher than in other populations. IS is also widespread in pigs and chickens, and causes significant economic impact in the associated industries. To date attempts to develop a vaccine against *B. pilosicoli* to protect humans and animals have not been successful.

In this study a reverse vaccinology approach was used, in which 24 putative open reading frames (ORFs) derived from a partial genome sequence of *B. pilosicoli* were subjected to *in silico* and laboratory screening processes to identify potential efficacious vaccine antigens. *In silico* analysis of the ORFs using a range of bioinformatics algorithms assigned 12 ORF products as periplasmic, outer membrane, or secretory proteins, and these were given a high priority as potential vaccine candidates. The 12 selected ORFs were amplified from a human strain of *B. pilosicoli* (Wes-B) and cloned. Products from nine ORFs were successfully over-expressed in an *Escherichia coli* expression system, and then purified using affinity chromatography.

In an *in vitro* immunogenicity trial all the recombinant proteins except for NAV-P27 were strongly recognised in Western immunoblots by a mouse serum raised against *B. pilosicoli* strain WesB, and by a subset of convalescent sera from pigs naturally and experimentally infected with *B. pilosicoli*. In an analysis of *in vivo* immunogenicity, the post-immunisation mouse sera raised against each recombinant protein reacted strongly with each specific proteins, and also recognised the native

protein in extracts of *B. pilosicoli* strain WesB. Sequence analysis of four randomly selected ORFs showed that these were highly conserved amongst the genomes of different human and swine strains of *B. pilosicoli*. Evaluation of all the data obtained in the reverse vaccinology approach resulted in selection of four ORF products (NAV-P3, NAV-13, NAV-22 and NAV-31) as being potentially protective antigens to be analysed for their further efficacy.

These four recombinant proteins were assessed for their efficacy as vaccine components in a mouse model of IS, where the animals were challenged with a human strain of *B. pilosicoli*. The proteins all induced systemic and local antibody responses, and tended to reduce spirochaete colonisation following experimental infection. These proteins used individually or in combination now have the potential to be further developed into a new vaccine to prevent *B. pilosicoli* infections.

ACKNOWLEDGEMENTS

To the many people whose help has been essential in bringing this thesis to fruition, my heartfelt thanks. First and foremost, my supervisor, Professor David Hampson, for his enthusiastic support, fantastic guidance, and encouragement. His constant source of knowledge, kindness and generosity were truly inspirational. I am also truly grateful for his enormous supports in my life.

My experiences and scientific progress at Murdoch University has been enriched immensely by the many friends that I have made. There are far too many to list, but suffice it to say that without them, my education here would have not been successful and enjoyable. A deep appreciation must be given to Dr. Mansour Heidari for his essential advice and help with cloning and expression techniques. I am eternally grateful to Dr. David Dunn and Yair Motro for their excellent suggestions and assistance in application of bioinformatic tools.

A word of appreciation must also be given to my friend Joshua Lewis for continuously sharing his knowledge and experiences and his great help and support when I encountered shortages of some reagents or equipment. A special thanks is also extended to my fellow PhD student and colleague Dr. Ram Naresh for providing me with a seed of *B. pilosicoli* strain WesB and his assistance with mice vaccinations. I wish also to thank Dr. Tom La and Dr. Nyree Philips for providing some of the necessary materials and goods which I needed. Thanks must also be extended to Dr. David Berryman, manager of the Western Australian State Agricultural Biotechnology Centre (SABC) at Murdoch University for guiding me through the use of the laboratory equipment.

Grateful acknowledgments are also made to the Razi Vaccine and Serum Research Institute and Ministry of Health and Medical Education of the Islamic

Republic of Iran for awarding me this PhD scholarship and supporting my family financially during this course. I would also like to credit Novartis Animal Vaccines and the Australian Research Council for providing funding for my research.

I would like to warmly thank my parents, whose eternal love and support provided the opportunities for my education leading up to this exploration of science. My special thanks also to my brother Dr. Alireza Movahedi, and my sister Mahdieh Movahedi for their great support and encouragement.

My eternal gratitude goes to my beloved wife, Zahra who believed in me and helped me through the difficulties, sorrows, joys and triumphs that I have faced during this educational process. This thesis would never have been accomplished without her patience, invaluable encouragement and constant inspiration. Lastly, a deeply heartfelt thanks to my sons Amin and Mahdi for their understanding and tolerance during these studies. Amin also proved to be an excellent assistant during the time of mice vaccination and efficacy trials.

PUBLICATION ARISING FROM THIS THESIS

Refereed papers in international journal:

Movahedi, A., Hampson, D.J. (2007) Distribution of the *clpX* gene in *Brachyspira* species and reactivity of recombinant *Brachyspira pilosicoli* ClpX with sera from mice and humans. *Journal of Medical Microbiology* 56: 930-936.

Movahedi, A., Hampson, D.J. (2008) Recent advances in identifying bacterial antigens for vaccine development. *Veterinary Microbiology* 131: 1-13

Movahedi, A., Hampson, D.J. (2009) A reverse vaccinology approach to identifying subunit proteins for use in vaccines against *Brachyspira pilosicoli* infections in humans and animals (manuscript in preparation).

Proceeding of international conference:

Movahedi, A., Hampson, D.J. (2007) Distribution of the *clpX* gene in *Brachyspira* species and reactivity of recombinant *B. pilosicoli* ClpX with human and animal sera. In: *Proceeding of the 4th International Conference on Colonic Spirochaetal Infections in Animals and Humans*, Prague. Czech Republic, Abstract 4.

Movahedi, A., Hampson, D.J. (2009) A reverse vaccinology approach to identifying subunit proteins for use in vaccines against *Brachyspira pilosicoli* infections in humans and animals (manuscript submitted in *5th International Conference on Colonic Spirochaetal Infections in Animals and Humans, Leon, Spain, June 8-10, 2009*).

Posters at Murdoch University

Movahedi, A., Hampson, D.J. (2004) Distribution, sequencing and expression of the *clpX* gene as a histidine-tag protein. School of Veterinary and Biomedical Sciences, Murdoch University, Western Australia, (Awarded the Invitrogen Life Technologies prize as the best poster on Molecular Microbiology).

Movahedi, A., Hampson, D.J. (2005) Reverse vaccinology and construction of recombinant protein library to develop a potential vaccine against human strains of *Brachyspira pilosicoli*. School of Veterinary and Biomedical Sciences, Murdoch University, Western Australia.

TABLE OF CONTENTS

TITLE PAGE	i
DEDICATION	ii
THESIS DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGMENT	vi
PUBLICATION ARISING FROM THIS THESIS	ix
TABLE OF CONTENT	ix
LIST OF TABLES	xvii
LIST OF FIGURES	xx
ABBREVIATIONS	xxiii

1. CHAPTER ONE – LITERATURE REVIEW

1.1 GENERAL INTRODUCTION	1
1.1.1 Preface	1
1.1.2 The spirochaetes	2
1.1.3 The <i>Brachyspira</i> genus	3
1.1.4 <i>Brachyspira pilosicoli</i>	5
1.1.4.1 Taxonomic and phylogenic position of <i>B. pilosicoli</i>	5
1.1.4.2 Morphology of <i>B. pilosicoli</i>	5
1.2 HUMAN INTESTINAL SPIROCHAETOSIS	6
1.2.1 Introduction	7
1.2.2 Aetiological agents of Human Intestinal Spirochaetosis (HIS)	7
1.2.3 Identification of the condition “intestinal spirochaetosis”	8
1.2.4 Clinical signs of human intestinal spirochaetosis	9
1.2.5 Prevalence of human intestinal spirochaetosis	10
1.2.5.1 Prevalence of IS using histological examination (agent unknown)	10
1.2.5.2 Prevalence of IS using histological examination (agents known)	11
1.2.5.3 Prevalence of IS using spirochaete isolation from faeces	12
1.2.6 Pathogenesis of human intestinal spirochaetosis	13
1.2.7 Sources and transmission of <i>B. pilosicoli</i>	14
1.2.8 Laboratory detection of human intestinal spirochaete	17

1.2.8.1 Morphological detection	17
1.2.8.2 Detection by culture	18
1.2.8.2.1 Solid media	18
1.2.8.2.2 Liquid medium	19
1.2.8.3 Biochemical identification	19
1.2.8.4 Detection by Polymerase Chain Reaction (PCR)	20
1.3 MOLECULAR GENETICS OF <i>B. PILOSICOLI</i>	21
1.3.1 Physical and genetic map of the <i>B. pilosicoli</i>	21
1.3.2 Beta-haemolysin gene (<i>Hly</i>)	22
1.3.3 RNA genes	25
1.3.4 Flagella-associated genes	25
1.3.5 Chromosomal replication genes	27
1.3.6 NADH oxidase gene	28
1.3.7 <i>Brachyspira</i> membrane proteins and lipoproteins	29
1.3.7.1 The <i>bhlp16</i> (<i>bmpA</i> or <i>smpA</i>) gene	30
1.3.7.2 The <i>bplp35</i> (<i>MgIB</i>) gene	32
1.3.7.3 The <i>bplp23</i> (<i>BmpC</i>) gene	33
1.3.7.4 The <i>clpX</i> gene	33
1.3.8 Metabolism and nutrient associated genes	34
1.4 VIRULENCE FACTORS OF SPIROCHAETES	35
1.4.1 Motility	35
1.4.2 Chemotaxis	36
1.5 IMMUNE RESPONSE	37
1.5.1 Humoral immunity	37
1.5.1.1 Systemic antibody response	37
1.5.1.2 Colonic antibody response	38
1.5.2 Cellular immunity	38
1.6 CONTROL OF INTESTINAL SIROCHAETOSIS	39
1.6.1 Use of antimicrobial agents	40
1.6.2 Eradication	41
1.6.3 Vaccines for <i>Brachyspira</i> infections	41
1.6.3.1 Killed vaccines	41
1.6.3.2 Attenuated vaccines	42
1.6.3.3 Recombinant subunit vaccines	43

1.6.3.4 DNA vaccines	44
1.7 THE “REVERSE VACCINOLOGY APPROACH”	45
1.7.1 Introduction	45
1.7.2 The application of reverse vaccinology in vaccine design	46
1.7.3 Advantages and disadvantages of reverse vaccinology	48
1.7.4 Genome-based approaches: strategies in vaccine design	49
1.7.4.1 <i>In silico</i> analysis for detection of virulence factors	51
1.7.4.2 <i>In silico</i> analysis for detection of secreted or surface-associated Proteins	52
1.7.4.3 Functional genomics in vaccine design	54
1.7.4.3.1 Proteomics	54
1.7.4.3.2 DNA microarray analysis	58
1.7.4.3.3 Other technologies	60
1.7.4.4 The pan-genomic approach in vaccine design	61
1.8 AIM, OBJECTIVES AND HYPOTHESIS OF THE PROJECT	63
2. CHAPTER TWO – MATERIALS AND METHODS	
2.1 INTRODUCTION	65
2.2 <i>IN SILICO</i> ANALYSIS OF THE SELECTED ORFS	66
2.2.1 Homology search	66
2.2.2 Domain or motif search	66
2.2.3 Prediction of subcellular location of ORFs products	66
2.2.4 Estimation of molecular weight and isoelectric pH (Iep) of ORFs Products	67
2.3 GENES DISTRIBUTION ANALYSIS BY PCR	68
2.3.1 Introduction	68
2.3.2 Strains	68
2.3.3 Cultivation of intestinal spirochaetes	68
2.3.4 Preparation of genomic DNA	70
2.3.4.1 Miniprep of bacterial genomic DNA using DNeasy™ Tissue Kit	70
2.3.4.2 Large scale preparation of bacterial genomic DNA using CTAB method	71
2.3.4.3 Genomic DNA quantification and qualification	71

2.3.5 Design and specification of primers for distribution studies	72
2.3.6 Polymerase chain reaction (PCR)	73
2.3.6.1 Polymerase chain reaction composition	76
2.3.6.2 PCR optimization and thermocycling conditions	76
2.3.7 Agarose gel electrophoresis	76
2.4 GENE SEQUENCING AND COMPARATIVE ANALYSIS	77
2.4.1 Introduction	77
2.4.2 Design and specification of primers for gene sequencing	80
2.4.3 Sequencing reactions	80
2.4.4 Gene similarity and phylogenetic analysis	81
2.5 RECOMBINANT DNA TECHNIQUES	82
2.5.1 Cloning and transformation	82
2.5.1.1 Preparation of competent <i>E. coli</i>	82
2.5.1.2 Designing of primers for cloning	83
2.5.1.3 PCR amplification of the gene of interest	83
2.5.1.4 DNA purification	83
2.5.1.4.1 Purification of PCR product	83
2.5.1.4.2 Purification of restriction digests	86
2.5.1.4.3 Purification of vector plasmids	87
2.5.1.4.4 Purification of sequencing reactions	88
2.5.1.5 Digestion of restricted DNA and vector DNA	88
2.5.1.6 Ligation of DNA	89
2.5.1.7 Transformation of competent <i>E. coli</i> cells	89
2.5.1.8 Screening of recombinant vector using direct colony PCR	90
2.5.1.9 Analysis of recombinant vector by sequencing	91
2.5.2 Recombinant protein expression	92
2.5.2.1 Screening of expressing clones	92
2.5.2.2 Determination of target protein solubility	93
2.5.2.3 Optimization of protein expression level	94
2.5.2.3.1 Selection of highly expressing clones	94
2.5.2.3.2 Time-course analysis of protein expression	95
2.5.2.3.3 Small-scale protein expression	95
2.5.2.3.4 Large-scale protein expression	96

2.5.3 Recombinant protein purification	96
2.5.3.1 Purification of soluble protein	96
2.5.3.2 Purification of insoluble protein	97
2.5.3.3 Protein treatment	98
2.5.4 Protein quantification and purity assays	98
2.5.4.1 SDS- polyacrylamide gel electrophoresis	98
2.5.4.2 Coomassie staining	99
2.5.4.3 Immunoblot detection of histidine tagged protein	99
2.5.4.4 Protein quantification	100
2.6 IMMUNOGENICITY ANALYSIS OF RECOMBINANT PROTEINS	101
2.6.1 <i>In Vitro</i> immunogenicity analysis	101
2.6.1.1 Immuno-blot reactivity of recombinant proteins with convalescent swine sera	101
2.6.1.2 Immuno-blot reactivity of recombinant proteins with mouse polyclonal antisera to WesB	102
2.6.2 <i>In Vivo</i> immunogenicity analysis	103
2.6.2.1 Immunizing mice using recombinant proteins	103
2.6.2.2 Western blot analysis of sera from mice immunised with recombinant proteins	103
2.7 EFFICACY ANALYSIS OF RECOMBINANT PROTEINS	105
2.7.1 Mice	105
2.7.2 Mouse diets	105
2.7.3 Preparation of challenge inoculum	106
2.7.4 Preparation and formulation of recombinant His ₆ -proteins for vaccination	106
2.7.5 Immunisation and experimental challenge	107
2.7.5.1 Faecal sampling, culture and DNA detection	109
2.7.5.2 Faecal samples, ELISA and mucosal IgG and IgA analysis	110
2.7.5.3 Blood samples	110
2.7.5.4 Post-mortem samples	111
2.7.6 Assays for antibody responses	111

2.7.6.1 Optimizing of ELISA conditions to analyse antibody responses	112
2.7.6.2 Optimizing Western blot conditions to analyze antibody responses	113
2.7.6.3 ELISA for systemic and colonic IgG and IgA	113
2.7.6.4 Western immunoblot analysis of systemic and colonic IgG and IgA	113
2.7.6.5 Data analysis and statistics	114

CHAPTER THREE - RESULTS

3.1 <i>IN SILICO</i> ANALYSIS OF PREDICTED ORFS	115
3.1.1 BlastP functional prediction	115
3.1.2 Protein domain prediction by Pfam analysis	115
3.1.3 Prediction of subcellular location	116
3.1.3.1 Prediction of location by PSORTb analysis	116
3.1.3.2 Analysing by SignalP	120
3.1.3.3 Prediction of lipoprotein signal peptide (SpII) by LipoP 1.0	120
3.1.3.4 TMpred	120
3.1.4 Calculation of G+C content and estimation of molecular weight of ORF products	124
3.2 DISTRIBUTION ANALYSIS OF THE CANDIDATE GENES AMONGST <i>B. PILOSICOLI</i> AND <i>B. AALBORGI</i> STRAINS	126
3.3 GENE CONSERVATION AMONGST <i>B. PILOSICOLI</i> STRAINS	131
3.3.1 Comparative analysis of the <i>NAV-PX</i> , <i>NAV-P3</i> , <i>NAV-P8</i> and <i>NAV-P9</i> genes and their proteins	131
3.3.2 Comparative analysis of the <i>NAV-PX</i> gene and <i>NAV-PX</i> protein	131
3.3.3 Phylogenetic analysis of <i>Brachyspira</i> spp. based on the <i>NAV-PX</i> sequences	133
3.4 GENERATION OF pTrcHis A RECOMBINANT PLASMID CONTAINING ORFs FOR <i>E. coli</i> EXPRESSION	134
3.5 RECOMBINANT PROTEIN EXPRESSION, PROTEIN SOLUBILITY, AND PROTEIN PURIFICATION	138

3.6 <i>IN VITRO</i> IMMUNOGENICITY ANALYSIS OF RECOMBINANT PROTEINS	145
3.6.1 Immuno-blot reactivity of recombinant proteins with convalescent swine sera	145
3.6.2 Immuno-blot reactivity of recombinant proteins with murine hyperimmune sera raised against <i>B. pilosicoli</i> strain WesB	145
3.7 <i>IN VIVO</i> IMMUNOGENICITY ANALYSIS OF RECOMBINANT PROTEINS	149
3.7.1 Immunising mice with recombinant proteins	149
3.8 TRIAL OF VACCINE EFFICACY USING THE RECOMBINANT PROTEINS IN MICE	154
3.8.1 Analysis of systemic antibody responses	154
3.8.1.1 Analysis of systemic antibody responses by ELISA	154
3.8.1.2 Analysis of systemic antibody responses by Western	154
3.8.2 Analysis of local antibody responses	160
3.8.2.1 Local IgG levels in samples obtained from the colon and caecum	160
3.8.2.2 Analysis of local IgG responses by Western blot	163
3.8.2.3 Analysis of local IgA responses	163
3.8.3 Faecal shedding of <i>B. pilosicoli</i> after infection	165
3.8.3.1 Efficacy trial I	165
3.8.3.1 Efficacy trial II	166
3.8.4 Clinical signs and pathological changes	170
CHAPTER FOUR - DISCUSSION	
4.1 INTRODUCTION	172
4.2 BIOINFORMATICS ANALYSIS	173
4.3 DISTRIBUTION ANALYSIS OF PUTATIVE ORFS	177
4.4 GENE SIMILARITY AND PHYLOGENETIC ANALYSIS	178
4.5 GENE CLONING AND PROTEIN EXPRESSION	179
4.6 <i>IN VITRO</i> AND <i>IN VIVO</i> IMMUNOGENICITY TRIALS	183
4.7 EFFICACY TRIALS IN A MOUSE MODEL	184

4.8 SUMMARY AND FURTHER WORK	191
REFERENCES	193
APPENDICES	
Appendix A. Equipments, chemicals, kits and software suppliers	228
A.1 Suppliers of laboratory instruments	228
A.2 Resources of chemicals, raw materials, and animals	229
A.3 Computer software suppliers	231
Appendix B. Formulation of buffers, solutions and culture media	232
B.1 Bacterial culture media	232
B.2 Buffers and solutions for SDS PAGE and Western blot	233
B.3 Buffers and solutions for genomic DNA preparation and gel electrophoresis	234
B.4 Buffers and solutions for ELISA	235
B.5 Buffers and solutions for protein purification	235
Appendix C. Sequence alignments	237
C.1 Multiple sequence alignment of <i>NAV-PX</i> gene in <i>Brachyspira</i> strains	237
C.2 Multiple sequence alignment of <i>NAV-P3</i> gene in <i>B. pilosicoli</i> strains	243
C.3 Multiple sequence alignment of <i>NAV-P8</i> gene in <i>B. pilosicoli</i> strains	244
C.4 Multiple sequence alignment of <i>NAV-P9</i> gene in <i>B. pilosicoli</i> strains	246

LIST OF TABLES

1.1	Some useful biochemical characteristics for differentiation of <i>B. pilosicoli</i> , <i>B. aalborgi</i> and <i>B. hyodysenteriae</i> type strains.	20
1.2	Genes localized in <i>Brachyspira</i> genomes, adopted from Zuerner <i>et al.</i> (2004)	24
1.3	The new nomenclature system for <i>Brachyspira</i> genes, membrane proteins, and lipoproteins.	30
2.1	<i>B. pilosicoli</i> and <i>B. aalborgi</i> strains used in gene distribution studies by PCR analysis.	69
2.2	Internal primers used for distribution study of the putative ORFs amongst different strains of intestinal spirochaetes.	74-75
2.3	Optimized PCR thermocycling conditions for distribution study of the putative ORFs using distribution primers.	78-79
2.4	PCR primes for sequencing of the <i>NAV-PX</i> , <i>NAV-P3</i> , <i>NAV-P8</i> , and <i>NAV-P9</i> genes.	81
2.5	Restricted oligonucleotides used for amplification of the putative ORFs in order to undertake gene cloning.	84-85
2.6	Vector-specific primers of pTrcHis A and pET-19b.	91
2.7	Optimized PCR thermocycling conditions for screening of recombinant vector plasmid using specific vector primers.	91
2.8	Source of sera from healthy swine (pre-infection) and swine that had been experimentally infected with <i>B. pilosicoli</i> .	102
2.9	Programme for efficacy trial of two experimental WesB recombinant subunit vaccines in groups of 12 five week-old C3H/HeJ mice.	108
2.10	The optimized PCR cycling conditions for screening of <i>B. pilosicoli</i> DNA in mice faecal samples.	110
3.1	Functional annotation of candidate genes (ORFs) by BlastP homology search.	117
3.2	Recognizing functional domains of candidate genes by sequence comparison using Pfam homology analysis.	118

LIST OF TABLES (Continued)

3.3	Prediction of subcellular localization of candidate gene products using the PSORTB v.2.0 analysis tool.	119
3.4	Prediction of signal peptide in ORFs products by SignalP 3.0 using neural networks (NN) and hidden Markov model (HMM) prediction for Gram-negative bacteria.	121
3.5	Prediction of lipoprotein signal peptide (signal peptidase II) in candidate gene products using LipoP 1.0.	122
3.6	Prediction of N-terminal transmembrane helices in candidate gene products using TMpred.	123
3.7	The G+C content of ORFs and theoretical molecular weight of their products.	125
3.8	PCR results of distribution analysis of the candidate genes amongst different strains of <i>B. pilosicoli</i> and <i>B. aalborgi</i> .	129
3.9	Summary of results of the gene distribution study by PCR amongst different strains of <i>B. pilosicoli</i> and <i>B. aalborgi</i> .	130
3.10	Peptide similarity between <i>B. pilosicoli</i> strain 95/1000 and candidate gene sequences obtained from six human and porcine strains of <i>B. pilosicoli</i> .	131
3.11	Amino acid substitutions in NAV-PX peptides of 8 strains of <i>B. pilosicoli</i> , and of <i>B. aalborgi</i> 513 ^T and <i>B. hyodysenteriae</i> 884 compared to the <i>B. pilosicoli</i> reference strain 95/1000 (accession no. AY466377).	132
3.12	Summary information about the recombinant pTrcHis A vector constructs containing ORFs.	135
3.13	Summary of recombinant protein expression and purification.	139
3.14	Alternative conditions for expression of NAV-P8, NAV-P9, and NAV-P45 gene products.	140
3.15	Results of immuno-blot reactions of purified recombinant proteins with a pool of pre-infected, and experimentally infected pig sera.	146
3.16	Means and standard deviations of group systemic IgG ELISA values in four groups of mice for each of four recombinant vaccine.	155

LIST OF TABLES (Continued)

3.17	Means and standard deviations of group local IgG ELISA values in four groups of mice during the vaccination trials.	160
3.18	Individual colonisation results for the vaccinated and non-vaccinated mice orally challenged with <i>B. pilosicoli</i> in efficacy trial I. Colonisation was determined by culture of faeces and PCR of the growth on the plates.	168
3.19	Individual colonisation results for the vaccinated and non-vaccinated mice orally challenged with <i>B. pilosicoli</i> in efficacy trial II. Colonisation was determined by culture of faeces and PCR of the growth on the plates.	169
3.20	Cumulative group colonisation results for the vaccinated and non-vaccinated mice orally challenged with <i>B. pilosicoli</i> in efficacy trials I and II.	170

LIST OF FIGURES

1.1	Phylogenetic tree based on almost complete sequences of 16S rDNA from 66 <i>Brachyspira</i> strains/isolates.	6
1.2	Dendrogram from multilocus enzyme electrophoresis data showing relationships between 107 isolates of <i>B. pilosicoli</i> originating from various host species located in electrophoretic types (ETs) 1–80 and <i>B. aalborgi</i> NCTC 11492T located in ET81.	16
1.3	Combined physical and genetic maps of <i>B. pilosicoli</i> strain P43/6/78 ^T .	23
1.4	Comparison of genetic organization of <i>B. pilosicoli</i> and <i>B. hyodysenteriae</i> .	23
1.5	Interplay between the different approaches in reverse vaccinology for vaccine design.	50
1.6	High throughput approaches in protein targeting and vaccine development.	55
3.1	Hydrophobicity analysis of the N-terminal 353 amino acids of NAV-P3.	124
3.2	Gel electrophoresis of the various genes showing distribution analysis by PCR. A) NAV-PX, B) NAV-P15, C) NAV-P31.	127
3.3	Gel electrophoresis of the various genes showing distribution analysis by PCR. A) NAV-P51, B) NAV-P15, C) NAV-P52.	128
3.4	Dendrogram constructed by the Neighbor-joining method from the MEGA 3.0 software using the entire 1785 bp NAV-PX gene.	133
3.5	Agarose gel electrophoresis from PCR screening of <i>E. coli</i> colonies harbouring the recombinant pTrcHis A vector containing NAV-P genes.	136
3.6	Chromatograms of constructed recombinant pTrcHis A containing NAV-P3 (A) and NAV-PX (B) genes.	137
3.7	Western blot screening of expressed histidine-tagged recombinant proteins using mouse monoclonal anti-polyhistidine antibody.	141
3.8	SDS-PAGE analysis of recombinant proteins expressed in <i>E. coli</i> .	142

LIST OF FIGURES (Continued)

- 3.9** **A)** Western blot detection of purified histidine-tagged recombinant proteins using mouse monoclonal anti-polyhistidine antibody. **B)** Coomassie-stained 12% SDS-PAGE gel of purified histidine-tagged recombinant proteins 143
- 3.10** Protein quantification by loading serial dilutions of recombinant protein samples in parallel with protein standards (BSA or mixture of BSA and lysosyme) on an SDS-PAGE gel and analysing the acquired destained gel image using a densitometer. 144
- 3.11** Western immuno-blot reactivity of recombinant proteins with porcine convalescent sera. **A)** NAV-PX protein, **B)** NAV-P13 protein. 147
- 3.12** Western immuno-blot reactivity of recombinant proteins with porcine convalescent sera. **A)** NAV-P31 protein, **B)** NAV-P22 protein. 148
- 3.13** Immuno-blot reactivity of purified recombinant proteins with murine hyperimmune sera against *B. pilosicoli* strain Wes B. 149
- 3.14** Western immuno-blot showing reactivity of recombinant proteins with their specific mice hyperimmune sera. **A)** NAV-P3 protein, **B)** NAV-P13 protein. 150
- 3.15** Western immuno-blot showing reactivity of recombinant proteins with their specific mice hyperimmune sera. **A)** NAV-P22 protein, **B)** NAV-P31 protein. 151
- 3.16** Western immuno-blot showing reactivity of mouse serum raised against recombinant proteins (**A:** NAV-P3 protein, **B:** NAV-P13 protein) with a whole cell preparation of *B. pilosicoli* strain WesB. 152
- 3.17** Western immuno-blot showing reactivity of mouse serum raised against recombinant proteins (**A:** NAV-P22 protein, **B:** NAV-P31 protein) with a whole cell preparation of *B. pilosicoli* strain WesB. 153
- 3.18** ELISA values (systemic IgG responses) of the mice vaccinated with experimental recombinant vaccines; **A)** NAV-P3; **B)** NAV-P13. 156
- 3.19** ELISA values (systemic IgG responses) of the mice vaccinated with experimental recombinant vaccines; **A)** NAV-P22; **B)** NAV-P31. 157

LIST OF FIGURES (Continued)

- 3.20** Western blot analysis of the systemic IgG responses of the mice 158
experimentally vaccinated with recombinant protein. **A)** Immunoblot
reactivity of NAV-P3 vaccinated sera to the whole cell preparation of
B. pilosicoli. **B)** Immunoblot reactivity of NAV-P13 vaccinated sera
to the whole cell preparation of *B. pilosicoli*.
- 3.21** Western blot analysis of the systemic IgG responses of the mice 159
experimentally vaccinated with recombinant protein. **A)** Immunoblot
reactivity of NAV-P22 vaccinated sera to the whole cell preparation of
B. pilosicoli. **B)** Immunoblot reactivity of NAV-P31 vaccinated sera
to the whole cell preparation of *B. pilosicoli*.
- 3.22** Local IgG responses measured by ELISA in mixed faecal samples 161
obtained at post-mortem from colons and caeca of the mice vaccinated
with experimental recombinant vaccines; **A)** NAV-P3 vaccine; **B)**
NAV-P13 vaccine.
- 3.23** Local IgG responses measured by ELISA in mixed faecal samples 162
obtained at post-mortem from colons and caeca of the mice vaccinated
with experimental recombinant vaccines; **A)** NAV-P22 vaccine; **B)**
NAV-P31 vaccine.
- 3.24** Western blot analysis of the local IgG responses of the mice 164
experimentally vaccinated with recombinant protein. **A)** Immunoblot
reactivity of NAV-P3 vaccinated faecal samples to the whole cell
preparation of *B. pilosicoli*. **B)** Immunoblot reactivity of NAV-P13
vaccinated faecal samples to the whole cell preparation of *B.*
pilosicoli.
- 3.25** Haematoxylin and eosin stained sections of caecal tissue from 171
C3H/HeJ mice infected with *B. pilosicoli* strain WesB.

ABBREVIATIONS

List of commonly used abbreviations in the thesis:

Abbreviation	Expansion
aa	Amino acid
A ₆₀₀	600 nm Absorbance
ABI	Applied Biosystems Inc.
AP	Alkaline phosphatase
ATCC	American Type Culture Collection
ATP	Adenosine-5'-triphosphate
bp	Base pair
BSA	Bovine serum albumin
dd water	Double distilled water
dil.	Dilution
DNA	Deoxyribonucleic Acid
DNAse	Deoxyribonuclease
DTT	Dithiothreitol
dNTP	Deoxynucleotide triphosphate
EDTA	Ethylenediaminetetra-acetic acid
ELISA	Enzyme-linked immunosorbent assay
FCA	Freund's incomplete adjuvant
FIA	Freund's complete adjuvant
Fig.	Figure
FCS	Foetal calf serum
g	Gram
h	Hour
HRP	Horse radish peroxidase
Ig	Immunoglobulin
IM	Intramuscular
IP	Intraperitoneal
IPTG	Isopropyl- β -D- thiogalactopyranoside
kbp	Kilobase pair
kDa	Kilo Daltons
L	Litre
LB	Luria-Bertani
LPS	Lipopolysaccharide
M	Molar
mM	Millimolar
MCS	Multiple cloning site
mg	Miligram

List of commonly used abbreviations in the thesis (continued):

Abbreviation	Expansion
min	Minute
ml	Mililitre
MW	Molecular Weight
ng	Nanogram
Ni-NTA	Nickel-nitriolotriacetic acid
nm	Nanometer
OD	Optical density
Oligo.	Oligonucleotide
OMP	Outer membrane protein
ORF	Open Reading Frame
PCR	Polymerase chain reaction
PBS	Phosphate buffered saline
PBST	Phosphate buffered saline containing 0.05% (v/v) Tween-20
PM	Post mortem
PMSF	Phenylmethylsulphonyl fluoride
pmol	Picomolar
ppm	Parts per million
RNase	Ribonuclease
rRNA	Ribosomal ribonucleic acid
RT	Room temperature
S	Second
SDS	Sodium dodecyl sulfate
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SC	Subcutaneous
spp.	Species
TAE	Tris-acetate EDTA buffer
TB	Terrific broth
TBS	Tris Buffered saline
TBST	Tris Buffered saline containing 0.05% (v/v) Tween-20
TE	Tris EDTA buffer
TEMED	N,N,N', N'-Tetramethyl-ethylendiamine
TSA	Trypticase soy agar
UV	Ultraviolet
v	Volume
w	Weight
µg	Microgram
µl	Microliter
µm	Micrometre
µM	Micromolar
